Rwanda: Senegal President in Rwanda for BioNTech Plant Launch

VIDEO: Inside BioNTech Rwanda
17 December 2023
The New Times (Kigali)
By Patrick Nzabonimpa

The plant is expected to start by producing 50 million vaccines, but the production will increase depending on the demand.

Senegal's President Macky Sall arrived in Rwanda on Sunday evening ahead of the inauguration of BioNTech Africa, a cutting-edge manufacturing facility for mRNA-based vaccines, on Monday, December 18.

President Sall was received by Minister of Finance and Economic Planning Uzziel Ndagijimana at the Kigali International Airport. Earlier on Sunday, the Senegalese Presidency posted a tweet on X saying that President Sall was set to travel to Kigali at the invitation of President Paul Kagame for the launch of BioNTech Africa.

À l'invitation de son homologue rwandais @PaulKagame, S.E. @Macky_Sall a quitté Dakar pour Kigali afin d'assister à l'inauguration de l'usine Biontech Africa, une usine de pointe pour la fabrication de vaccins ARN messager destinée à lutter contre le paludisme et la tuberculose. pic.twitter.com/Tw8BKWhlE3-- Présidence Sénégal (@PR_Senegal) December 17, 2023

Since 2021, the government of Rwanda has been working with BioNTech, a renowned German biotechnology company on the construction of the manufacturing plant for mRNA-based vaccines.

mRNA vaccines work by providing body cells with instructions to produce a harmless part of the virus, teaching the immune system to recognise and defend against it. These vaccines do not contain live viruses and cannot cause the disease, offering a safe and effective way to build immunity.

In 2021, a memorandum of understanding between the two parties paved the way for creating a BioNTech facility in the Special Economic Zone in Gasabo District.

Following months of dedicated efforts, including the shipping and installation of BioNTainers--facilities designed for manufacturing a variety of mRNA-based vaccines--the factory is now ready.

Spanning approximately 30,000 square metres, the Rwanda-based facility is equipped with BioNTainers specifically tailored for the production of mRNA and formulated bulk drug products.

The plant is expected to start by producing 50 million vaccines, but the production will increase depending on the demand.

According to BionTech, the facility is expected to become the first node in Africa's decentralised and robust end-to-end manufacturing network.

Aside from Kigali, BioNTech, in March, said it plans to ship BioNTainers to Senegal and "potentially" South Africa.

President Sall's most recent appearance in Rwanda was in July at the Women Deliver Conference, during which he pledged 150 scholarships for Afghan girls pursuing studies in the country.

Read the original article on New Times.

Tagged:
Copyright © 2023 The New Times. All rights reserved. Distributed by AllAfrica Global Media (allAfrica.com). To contact the copyright holder directly for corrections — or for permission to republish or make other authorized use of this material, click here.

AllAfrica publishes around 500 reports a day from more than 100 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.